Current Progress and Future Developments of Antibody Drug Conjugates
in Lung Cancer.
10.3779/j.issn.1009-3419.2022.102.22
- Author:
Yixiang ZHU
1
;
Zhijie WANG
1
Author Information
1. CAMS Key Laboratory of Translational Research on Lung Cancer, State Key Laboratory of Molecular Oncology,
Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,
Chinese Academy of Medical Sciences Peking Union Medical College, Beijing 100021, China.
- Publication Type:Journal Article
- Keywords:
Antibody drug conjugates (ADCs);
Lung neoplasms;
Precision medicine
- MeSH:
Antibodies, Monoclonal/therapeutic use*;
Antineoplastic Agents/therapeutic use*;
Antineoplastic Agents, Immunological/therapeutic use*;
Humans;
Immunoconjugates/therapeutic use*;
Lung Neoplasms/drug therapy*;
Neoplasms/drug therapy*
- From:
Chinese Journal of Lung Cancer
2022;25(7):468-476
- CountryChina
- Language:Chinese
-
Abstract:
Antibody drug conjugates (ADCs) are a novel class of anti-cancer drugs, which combined the specificity of monoclonal antibodies with the cytotoxic palyload via the linkers. Many ADCs have not only verified impressive activity in a variety of cancers, including breast cancer and hematological system tumors, but also in lung cancer. The aim of this study was to provide informations for practice by summarizing the mechanism of action, clinical application and problems and challenges of ADCs.
.
